Kangzhe Pharmaceutical

We collaborate with global biotechnology (or pharmaceutical) companies to build an open, cooperative, and win-win medical innovation ecosystem, enhancing the efficiency of pharmaceutical innovation and R&D.

We possess a management system and professional team that control key nodes across the full lifecycle of innovative products, expert resources in a wide range of specialized disease areas, abundant self-owned cash flow, and profound market insight. This enables us to identify and explore products addressing unmet clinical needs, efficiently advance the clinical development and commercialization process of innovative products, empower the continuous transformation of scientific research achievements into clinical diagnosis and treatment practice, and benefit more patients.

We deeply cultivate specialized disease areas such as cardiovascular and cerebrovascular, digestion, central nervous system, dermatology/medical aesthetics, ophthalmology, pediatrics, among others. The market position achieved by our main products on sale has driven the Group's continuous high-speed growth in operating performance. Over the past fifteen years (2008-2022), the compound annual growth rate of the Group's sales revenue and net profit both exceeded 20%.

Furthermore, through independent operation of specialized business lines, we further integrate superior resources in specialized disease areas, building highly professional teams with focus and internal drive. Benefiting from the synergy and sharing of group-level resources, we enhance the scale efficiency of specialized business, cultivate leaders in niche specialized fields; meanwhile, we expand our business footprint to the Southeast Asian market to obtain additional growth contributions, promoting the Group's high-quality, sustainable, and healthy development.